Alberto Caballero Vázquez1, Paula García Flores1, Ana Romero Ortiz1, Raimundo García Del Moral2, Bernardino Alcázar-Navarrete3,4. 1. Servicio de Neumología, Hospital Universitario Virgen de las Nieves, Granada, Spain. 2. UGC de Anatomía Patológica, Complejo Hospitalario Universitario de Granada, Granada, Spain. 3. AIG de Medicina, Hospital de Alta Resolución de Loja, Agencia Sanitaria Hospital de Poniente, Loja, Granada, Spain. 4. Centro de investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Abstract
BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of death all over the world. Diagnostic and therapeutic arsenals have improved in recent years, but we are unsure as to whether these advances have been transferred to clinical practice. The aim of this study was to evaluate differences in NSCLC diagnostic processes and short-term survival rates between two recent cohorts. METHODS: A prospective, observational study was conducted with patients diagnosed with NSCLC in the period of 2011-2016. Patients were divided into two cohorts (2011-2013 and 2014-2016), and monitored for up to 1 year after diagnosis. RESULTS: A total of 713 patients with lung cancer were selected, 500 of whom had NSCLC (222 patients in the 2011-2013 cohort, and 278 in the 2014-2016 cohort). We observed a chronological increase in the use of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) and ultrasound-guided transthoracic puncture (US-TTP) between the cohorts. Overall short-term survival was similar between the two groups, both for locally and for advanced disease. Treatment with tyrosine kinase inhibitors (TKI) was the only therapeutic factor associated with an improved likelihood of survival. CONCLUSIONS: Changes in diagnostic process in NSCLC have been observed towards a more precise stratification. Although short-term survival has not changed for advanced NSCLC, some of the newer therapeutic options are associated with increased survival in real-world scenarios.
BACKGROUND: Non-small cell lung cancer (NSCLC) is a leading cause of death all over the world. Diagnostic and therapeutic arsenals have improved in recent years, but we are unsure as to whether these advances have been transferred to clinical practice. The aim of this study was to evaluate differences in NSCLC diagnostic processes and short-term survival rates between two recent cohorts. METHODS: A prospective, observational study was conducted with patients diagnosed with NSCLC in the period of 2011-2016. Patients were divided into two cohorts (2011-2013 and 2014-2016), and monitored for up to 1 year after diagnosis. RESULTS: A total of 713 patients with lung cancer were selected, 500 of whom had NSCLC (222 patients in the 2011-2013 cohort, and 278 in the 2014-2016 cohort). We observed a chronological increase in the use of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) and ultrasound-guided transthoracic puncture (US-TTP) between the cohorts. Overall short-term survival was similar between the two groups, both for locally and for advanced disease. Treatment with tyrosine kinase inhibitors (TKI) was the only therapeutic factor associated with an improved likelihood of survival. CONCLUSIONS: Changes in diagnostic process in NSCLC have been observed towards a more precise stratification. Although short-term survival has not changed for advanced NSCLC, some of the newer therapeutic options are associated with increased survival in real-world scenarios.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); advanced disease; molecular testing
Authors: Claribel P Simmons; Filippos Koinis; Marie T Fallon; Kenneth C Fearon; Jo Bowden; Tora S Solheim; Bjorn Henning Gronberg; Donald C McMillan; Ioannis Gioulbasanis; Barry J Laird Journal: Lung Cancer Date: 2015-03-28 Impact factor: 5.705
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi Journal: Arch Pathol Lab Med Date: 2013-04-03 Impact factor: 5.534
Authors: Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609
Authors: F M Walter; G Rubin; C Bankhead; H C Morris; N Hall; K Mills; C Dobson; R C Rintoul; W Hamilton; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Daan van den Broek; T Jeroen N Hiltermann; Bonne Biesma; Winand N M Dinjens; Nils A 't Hart; John W J Hinrichs; Mathie P G Leers; Kim Monkhorst; Matthijs van Oosterhout; Volkher Scharnhorst; Ed Schuuring; Ernst-Jan M Speel; Michel M van den Heuvel; Ron H N van Schaik; Jan von der Thüsen; Stefan M Willems; Leonie de Visser; Marjolijn J L Ligtenberg Journal: Front Oncol Date: 2020-01-22 Impact factor: 6.244